Recent Advances in Cardiovascular Risk Reduction: Implications of ONTARGET

Clinical Cornerstone

Volumn 9, Issue SUPPL. 3, 2009, Pages

  Guthrie, Robert ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; INOTROPIC AGENT; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SYNCOPE;

EID: 65249095355     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)60015-6     Document Type: Article

References (24)

1. Jackson E.K., and Garrison J.C. Renin and angiotensin. In: Hardman J.G., and Limbird L.E. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition (1996), McGraw-Hill, New York, NY
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
4. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
5. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342:1376; N Engl J Med. 2000;342:748]. N Engl J Med 342 (2000) 145-153
8. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
9. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 (2002) 995-1003
10. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 362 (2003) 759-766
11. Cohn J.N., Tognoni G., and for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
12. Yusuf S., Teo K.K., Pogue J., et al., for the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
13. Benowitz N.L. Antihypertensive agents. In: Katzung B.G. (Ed). Basic & Clinical Pharmacology. Sixth Edition (1995), Appleton & Lange, Norwalk, Conn
14. National Heart, Lung, and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (2003), National Institutes of Health, US Dept of Health and Human Services
15. Rodriguez-Granillo G.A., de Winter S., Bruining N., et al., for the EUROPA/PERSPECTIVE Investigators. Effect of perindopril on coronary remodelling: Insights from a multicentre, randomized study. Eur Heart J 28 (2007) 2326-2331
16. Ceconi C., Fox K.M., Remme W.J., et al., for the EUROPA Investigators, PERTINENT Investigators and the Statistical Committee. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 73 (2007) 237-246
17. Brugts J.J., Boersma E., Choncol M., et al., for the EUROPA Investigators. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: Insights from the EUROPA trial. J Am Coll Cardiol 50 (2007) 2148-2155
18. Fox K.M., Bertrand M.E., Remme W.J., et al., for the EUROPA Investigators. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. Am Heart J 153 (2007) 629-635
19. Daly C.A., Fox K.M., Remme W.J., et al., for the EUROPA Investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: Results from the PERSUADE substudy. Eur Heart J 26 (2005) 1369-1378
20. Deckers J.W., Goedhart D.M., Boersma E., et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 27 (2006) 796-801
21. Granger C.B., McMurray J.J., Yusuf S., et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 362 (2003) 772-776
22. McMurray J.J., Ostergren J., Swedberg K., et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 362 (2003) 767-771
23. Yusuf S., Teo K., Anderson C., et al., for the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial [published correction appears in Lancet. 2008;372:1384]. Lancet 372 (2008) 1174-1183
24. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [published correction appears in N Engl J Med. 2004;350:203]. N Engl J Med 349 (2003) 1893-1906